Is COO a good stock to buy?
The Cooper Companies, Inc. · end-of-day data as of Nov 13, 2026
- ConsensusBuy · 18
- P/E vs own-45.0%
- P/E vs sector-33.6%
- FCF yield+5.7%
- Insiders$1.88M
- MA20×50Golden 5d ago
- MACD0.16
- Sector▲ +15.9%
- Earnings in20d
- P/E21.4x
- RSI57
- Support-0.6%
- Resistance+3.1%
- Off 52w high-30.3%
- Volume0.6x
- Bollingerupper half
- News0.00
- PT$65.11 +3.9%
- 52w range$51–$90
- ATR+2.7%
- Off ATH-45.9%
- MAs2 of 4
- Trendbearish
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Cooper Companies a good stock to buy?
Cooper Companies is strong on 2 of the 5 questions about the business; weak on advantage. The price is low: 21.4 times its earnings, below its 3-year median of 49.5 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand steady
- Advantage easy to copy
- Economics profitable
- Execution delivers
- Fragility sturdy
- Price below its usual
COO sales growth revenue growth
+7%a year, for the last 3 yearsCooper Companies' sales grew 7% a year for 3 years, to $4.09B in fiscal 2025.
COO analysts' forecast revenue estimates
+4%the sales they expect next fiscal year, on the lastAnalysts expect Cooper Companies' sales to grow 4% to $4.24B in fiscal 2026 (13 analysts).
COO competitors
pretickt analysis+5%its sales in 12 months, on a year before
Cooper Companies' sales grew 5% in the 12 months to Jul 31, 2026, faster than Solventum (-3%), slower than West Pharmaceutical Services (+13%), ResMed (+9%) and Baxter (+5%).
COO sales by business revenue by segment
67%of its sales from CoopervisionCoopervision brought Cooper Companies 67% of its sales in fiscal 2025; Coopersurgical 33%.
COO margin after costs profit margin
13%of sales left after running the businessCooper Companies' operating margin was 13% in the 12 months to Jul 31, 2026, against 15% in fiscal 2022.
COO cash generated free cash flow
$678Mcash left after investing, last 12 monthsCooper Companies generated $678M of free cash flow in the 12 months to Jul 31, 2026, more than its reported profit.
COO earnings vs estimates
8 of 8quarters above the analysts' estimateCooper Companies beat the analysts' profit estimate in each of its last 8 quarters, the latest on Sep 9, 2026.
COO insider buying
+$3.18Mbought, net, by its executives in 12 monthsCooper Companies' executives and directors bought a net $3.18M of shares in the 12 months to Nov 13, 2026; none sold.
COO number of employees
-6%fewer people in a yearCooper Companies had 15,000 employees at the end of fiscal 2025, 6% fewer than a year before.
COO CEO pay
$16.05Mfor fiscal 2025, 83% of it in stock and optionsCooper Companies paid its CEO $16.05M for fiscal 2025, 83% of it in stock and options.
COO financial health Altman Z-score
3.1Altman Z-score, safe above 3Cooper Companies' Altman Z-score is 3.1 (Nov 13, 2026), above 3, where the safe zone starts.
COO quality checks Piotroski score
7 of 9checks passedCooper Companies passes 7 of the 9 Piotroski checks in the 12 months to Jul 31, 2026; it misses on the current ratio and gross margin.
COO biggest customers
under 10%of sales from any one customerNo customer made 10% of Cooper Companies' sales in fiscal 2025.
COO in past recessions
pretickt analysis-8%its sales in the worst oneCooper Companies' sales fell in 1 of the last 2 US recessions, by as much as 8% in fiscal 2020.
COO price vs profit P/E ratio
21.4×a year's earningsCooper Companies' P/E ratio is 21.4 (Nov 13, 2026), below its 3-year median of 49.5.
COO price vs competitors
pretickt analysis21.4×a year's earnings, against its competitorsInvestors pay 21.4 times Cooper Companies' earnings (Nov 13, 2026), less than for Solventum (99.0), West Pharmaceutical Services (46.7) or ResMed (21.9).
COO analysts' target price target
+4%to their average targetAnalysts' average price target for Cooper Companies is $65.11, 4% above the Nov 13, 2026 close of $62.65.
COO analyst ratings, 90 days
pretickt analysisB of A Securitiesdowngrade Bairddowngrade Piper Sandlerdowngrade William Blairdowngrade
In the 90 days to Nov 13, 2026, B of A Securities, Baird, Piper Sandler and William Blair downgraded Cooper Companies.
COO growth priced in fair value
pretickt analysis+5%a year, for ten years, to be worth the priceAt $62.65 a share, Cooper Companies' free cash flow must grow about 5% a year for ten years to be worth the price (Nov 13, 2026).
What is Cooper Companies' P/E ratio?
Cooper Companies' P/E ratio is 21.4 (Nov 13, 2026), below its 3-year median of 49.5. Investors pay 21.4 times Cooper Companies' earnings (Nov 13, 2026), less than for Solventum (99.0), West Pharmaceutical Services (46.7) or ResMed (21.9).
Who are Cooper Companies' biggest competitors?
pretickt compares Cooper Companies with Baxter, Solventum, West Pharmaceutical Services and ResMed. Cooper Companies' sales grew 5% in the 12 months to Jul 31, 2026, faster than Solventum (-3%), slower than West Pharmaceutical Services (+13%), ResMed (+9%) and Baxter (+5%).
Is Cooper Companies profitable?
Cooper Companies' operating margin was 13% in the 12 months to Jul 31, 2026, against 15% in fiscal 2022. Cooper Companies generated $678M of free cash flow in the 12 months to Jul 31, 2026, more than its reported profit.
Are insiders buying Cooper Companies stock?
Cooper Companies' executives and directors bought a net $3.18M of shares in the 12 months to Nov 13, 2026; none sold.
How does Cooper Companies make money?
Coopervision brought Cooper Companies 67% of its sales in fiscal 2025; Coopersurgical 33%.
How many employees does Cooper Companies have?
Cooper Companies had 15,000 employees at the end of fiscal 2025, 6% fewer than a year before.
Who are Cooper Companies' biggest customers?
No customer made 10% of Cooper Companies' sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.